Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$16.34
-4.7%		$23.73
$11.92
▼
$27.31
$3.05B1.082.22 million shs1.17 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$8.79
-8.9%		$10.91
$6.65
▼
$36.26
$769.83M1.981.38 million shs594,438 shs
uniQure N.V. stock logo
QURE
uniQure
$43.48
-4.0%		$44.60
$8.73
▼
$71.50
$3.00B0.942.28 million shs443,496 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$26.27
-2.2%		$28.33
$12.15
▼
$31.74
$3.34B0.811.28 million shs739,449 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.12%-4.25%-34.33%-15.69%+27.53%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
+0.10%-1.43%-9.82%-13.46%+15.46%
uniQure N.V. stock logo
QURE
uniQure
+2.19%+5.06%-6.39%-7.31%+227.40%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+3.56%+11.07%-10.70%-6.35%+114.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$16.34
-4.7%		$23.73
$11.92
▼
$27.31
$3.05B1.082.22 million shs1.17 million shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$8.79
-8.9%		$10.91
$6.65
▼
$36.26
$769.83M1.981.38 million shs594,438 shs
uniQure N.V. stock logo
QURE
uniQure
$43.48
-4.0%		$44.60
$8.73
▼
$71.50
$3.00B0.942.28 million shs443,496 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$26.27
-2.2%		$28.33
$12.15
▼
$31.74
$3.34B0.811.28 million shs739,449 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.12%-4.25%-34.33%-15.69%+27.53%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
+0.10%-1.43%-9.82%-13.46%+15.46%
uniQure N.V. stock logo
QURE
uniQure
+2.19%+5.06%-6.39%-7.31%+227.40%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+3.56%+11.07%-10.70%-6.35%+114.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.81
Moderate Buy$32.1796.86% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.77
Moderate Buy$40.60362.15% Upside
uniQure N.V. stock logo
QURE
uniQure
2.76
Moderate Buy$65.0049.50% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.64
Moderate Buy$38.3045.77% Upside

Current Analyst Ratings Breakdown

Latest OLMA, RCUS, DYN, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/21/2026
uniQure N.V. stock logo
QURE
uniQure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/16/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/14/2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$48.00 ➝ $30.00
9/11/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $36.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $26.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$35.00 ➝ $30.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Underweight$17.00 ➝ $10.00
9/8/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$37.00
9/8/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00 ➝ $40.00
(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$5.88 per shareN/A
uniQure N.V. stock logo
QURE
uniQure
$16.10M187.33N/AN/A$3.19 per share13.63
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M13.54N/AN/A$5.84 per share4.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$162.45M-$2.12N/AN/AN/AN/A-48.26%-43.04%11/9/2026 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.90N/AN/AN/A-393.16%-89.54%-45.61%10/27/2026 (Estimated)

Latest OLMA, RCUS, DYN, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.5515-$0.61-$0.0585-$0.61N/AN/A
8/5/2026Q2 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.8912-$0.72+$0.1712-$0.72$21.98 million$41.00 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.01
8.86
8.86
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.22
3.82
3.82

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
uniQure N.V. stock logo
QURE
uniQure
78.83%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
12.56%
uniQure N.V. stock logo
QURE
uniQure
4.65%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
258186.75 million169.08 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
15087.50 million76.51 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
601127.33 million117.66 millionOptionable

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Trading Up 3.2% - Should You Buy?
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-arcus-biosciences-nyse-rcus-trading-up-32-should-you-buy-2026-09-23/
Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy
September 22 at 3:42 PM  |  marketscreener.comM
Arcus Biosciences (RCUS) Reiterated at Overweight by Cantor Fitzgerald
September 22 at 3:42 PM  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Arcus+Biosciences+%28RCUS%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald/27088045.html
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
September 22 at 3:42 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arcus-biosciences-host-investor-event-123000502.html
Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals
September 21 at 8:22 AM  |  ad-hoc-news.deA
Squarepoint Ops LLC Decreases Stake in Arcus Biosciences, Inc. $RCUS
September 21 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-decreases-stake-in-arcus-biosciences-inc-rcus-2026-09-21/
TD Cowen Initiates Arcus Biosciences at Buy
September 16, 2026  |  marketscreener.comM
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025832
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Analysts
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-arcus-biosciences-inc-nyse-rcus-receives-consensus-rating-of-moderate-buy-from-analysts-2026-09-16/
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946642-arcus-biosciences-inc-rcus-presents-at-morgan-stanley-24th-annual-global-healthcare
Arcus Biosciences (NYSE:RCUS) Shares Down 5.6% - Here's What Happened
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-arcus-biosciences-nyse-rcus-shares-down-56-heres-what-happened-2026-09-11/
Arcus Biosciences Announces New Employment Inducement Grants
September 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260909120397/en/arcus-biosciences-announces-new-employment-inducement-grants/
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944552-arcus-biosciences-inc-rcus-presents-at-citigroups-biopharma-back-to-school-summit-2026
Allianz Asset Management GmbH Purchases New Stake in Arcus Biosciences, Inc. $RCUS
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-purchases-new-stake-in-arcus-biosciences-inc-rcus-2026-09-09/
42,338 Shares in Arcus Biosciences, Inc. $RCUS Acquired by Jupiter Topco LLC
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-42338-shares-in-arcus-biosciences-inc-rcus-acquired-by-jupiter-topco-llc-2026-09-05/
Arcus Biosciences Advances Casdatifan With New Liver Function Study
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arcus-biosciences-advances-casdatifan-with-new-liver-function-study?utm_source=marketbeat.com&utm_medium=referral
The Manufacturers Life Insurance Company Makes New $1.41 Million Investment in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-makes-new-141-million-investment-in-arcus-biosciences-inc-rcus-2026-09-04/
Legal & General Group Plc Invests $5.91 Million in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-591-million-in-arcus-biosciences-inc-rcus-2026-09-04/
Corient Private Wealth LP Invests $1.82 Million in Arcus Biosciences, Inc. $RCUS
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-invests-182-million-in-arcus-biosciences-inc-rcus-2026-09-04/
Arcus Biosciences, Inc. $RCUS Position Decreased by Montanova Capital LLC
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arcus-biosciences-inc-rcus-position-decreased-by-montanova-capital-llc-2026-09-01/
Wellington Management Group LLP Sells 194,068 Shares of Arcus Biosciences, Inc. $RCUS
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-sells-194068-shares-of-arcus-biosciences-inc-rcus-2026-09-01/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Desk with a monitor showing an upward stock price chart, printed financial reports, and a bronze bull statue.
3 Earnings Season Winners That Analysts Can't Stop Upgrading
By Dan Schmidt | September 7, 2026
Digital illustration of glowing servers, cloud icons, and data charts connected by light streams, symbolizing cloud computing and data networks.
3 Software Stocks Rebounding as AI Fears Give Way to Growth
By Leo Miller | September 21, 2026
Worker in a safety vest and hard hat inspects steel beams inside a metal fabrication warehouse near rail cars.
Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
By Chris Markoch | September 22, 2026
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$16.34 -0.80 (-4.67%)
As of 01:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$8.78 -0.86 (-8.87%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

uniQure stock logo

uniQure NASDAQ:QURE

$43.48 -1.80 (-3.98%)
As of 01:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$26.27 -0.60 (-2.22%)
As of 01:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas